A network meta-analysis comparing alemtuzumab to natalizumab in patients with relapsing-remitting multiple sclerosis with rapidly evolving severe disease

被引：0
|
作者：
Guo, J. D. [1 ]
Das Gupta, R. J. [1 ]
Fahrbach, K. [2 ]
Wissinger, E. [2 ]
Cox, F. M. [1 ]
机构：
[1] Sanofi Genzyme, Cambridge, MA USA
[2] Evidera, Bethesda, MD USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1479
引用
收藏
页码：772 / 772
页数：1
相关论文
共 50 条
  • [1] Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
    Huisman, Eline
    Papadimitropoulou, Katerina
    Jarrett, James
    Bending, Matthew
    Firth, Zoe
    Allen, Felicity
    Adlard, Nick
    BMJ OPEN, 2017, 7 (03):
  • [2] NATALIZUMAB VERSUS GLATIRAMER ACETATE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS
    Sultanov, M.
    Almadiyeva, A.
    Absattarova, K.
    Semenova, Y.
    VALUE IN HEALTH, 2018, 21 : S331 - S331
  • [3] IMMUNOMODULATORS AND IMMUNOSUPPRESSANTS FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS: A NETWORK META-ANALYSIS
    Lucchetta, R. C.
    Tonin, F. S.
    Borba, H. H.
    Leonart, L. P.
    Ferreira, V. L.
    Bonetti, A. F.
    Riveros, B. S.
    Becker, J.
    Pontarolo, R.
    Fernandez-Llimos, F.
    Wiens, A.
    VALUE IN HEALTH, 2018, 21 : S203 - S204
  • [4] Systematic Review and Meta-Analysis Comparing the Safety of Natalizumab, Ocrelizumab, and Alemtuzumab in Treating Relapsing-Remitting, Primary Progressive, and Secondary Progressive Multiple Sclerosis
    Raina, Pooja
    Basu, Somnath
    Goyal, Ramesh K.
    Sahoo, Pravat K.
    Mathur, Rajani
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2022, 13 (01) : 14 - 23
  • [5] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [6] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [7] Comparative effectiveness of natalizumab, fingolimod, and first-line therapies for rapidly evolving severe relapsing-remitting multiple sclerosis
    Spelman, T.
    Acosta, C.
    Hyde, R.
    Campbell, N.
    Havrdova, E.
    Horakova, D.
    Trojano, M.
    De Luca, G.
    Lugaresi, A.
    Izquierdo, G.
    Grammond, P.
    Duquette, P.
    Alroughani, R.
    Pucci, E.
    Granella, F.
    Lechner-Scott, J.
    Sola, P.
    Ferraro, D.
    Grand-Maison, F.
    Terzi, M.
    Rozsa, C.
    Boz, C.
    Hupperts, R.
    Van der Walt, A.
    Van Pesch, V.
    Oreja-Guevara, C.
    Jokubaitis, V.
    Kalincik, T.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 526 - 527
  • [8] Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis
    Gomez, Pablo Rodriguez de Vera
    Muros, Mariola Mendez
    Cuadro, Alberto Torres
    de Miera, Francisco Javier Toyos Saenz
    Ruiz, Rocio Lopez
    Vazquez, Raquel Guerrero
    Gonzalez, Juan Jesus Garcia
    Hermosilla, Antonio Manuel Garrido
    Hernandez, Tomas Martin
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 486 - 496
  • [9] Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
    Tramacere, Irene
    Del Giovane, Cinzia
    Salanti, Georgia
    D'Amico, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (09):
  • [10] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
12345